Phenotyping Embryonic Lethal Knockout Mice (R01) | Apply Online

Opportunity Summary:

The NIH funding opportunity PAR 13-231, titled "Phenotyping Embryonic Lethal Knockout Mice (R01)," is a discretionary grant program designed to push forward the detailed biological characterization of knockout (KO) mouse strains that do not survive embryonic or early postnatal development. These lethal or perinatal lethal lines are being produced through the International Mouse Phenotyping Consortium (IMPC), a large coordinated international effort to create and phenotype thousands of gene knockout strains, with the NIH Knockout Mouse Phenotyping Program (KOMP2) participating as a member. The central idea behind the FOA is that the field has a narrow but valuable window of time to study these lines as they are being generated and bred for the broader IMPC adult phenotyping pipeline, and that researchers can extract major insights from embryonic and developmental stages that are otherwise missed when only viable adult mice are examined.

A key scientific motivation is scale and opportunity. Over roughly a decade, IMPC-related efforts were projected to generate around 20,000 KO mouse strains, and a meaningful subset is expected to show embryonic or perinatal lethality. The announcement highlights that many homozygous lethal mutations can still produce informative, viable heterozygous phenotypes, meaning even when a full knockout cannot survive, there may be detectable and clinically relevant traits in carriers. This creates a strong rationale for focused phenotyping approaches that capture developmental defects, organogenesis problems, early physiological failures, and other mechanisms that explain why loss of a given gene is incompatible with life. In practice, the FOA is aiming to fill an important knowledge gap: without targeted embryonic phenotyping, lethal lines risk being underexplored even though they may be among the most informative for understanding essential gene functions, congenital disease mechanisms, and developmental pathways.

Mechanistically, this opportunity uses the NIH R01 grant mechanism, meaning it is intended for hypothesis-driven, investigator-initiated research projects that can stand on their own scientific aims while leveraging the availability of IMPC-generated mouse resources. The FOA is not framed as cost sharing or matching; there is no cost-sharing requirement. The maximum award amount listed is an award ceiling of $499,999, establishing an upper bound for proposed budgets under this specific opportunity. While the underlying IMPC program is known for standardized pipelines, this FOA focuses on encouraging the broader scientific community to propose rigorous phenotyping strategies for lethal lines, including careful staging, anatomical and physiological assessment, and methods appropriate to embryonic or perinatal timepoints, rather than relying only on adult phenotyping protocols.

The program is administered by the National Institutes of Health and is associated with multiple CFDA numbers reflecting the cross-cutting relevance of these models to different disease and biology areas. The included CFDA listings span human genome research (93.172) and major disease research portfolios such as cardiovascular (93.837), diabetes/digestive/kidney (93.847), and child health and human development (93.865). That breadth signals that the NIH sees embryonic lethal phenotypes as foundational science with downstream impact across many organ systems and disease domains, from congenital heart defects and metabolic syndromes to neurodevelopmental disorders and other early-onset conditions.

Eligibility is broad and intentionally inclusive, covering many types of domestic and international institutions. Eligible applicants include state, county, city/township, special district governments, tribal governments and tribal organizations, public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses), independent school districts, and public housing authorities/Indian housing authorities. The FOA also explicitly includes a wide range of institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISIs, along with faith-based or community-based organizations where appropriate. Importantly, non-U.S. entities are eligible to apply, foreign institutions are eligible, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined under the NIH Grants Policy Statement. This structure aligns with the global nature of IMPC resources and the reality that expertise in embryology, imaging, pathology, and developmental genetics is distributed across many countries and sectors.

In terms of timeline, the FOA was posted and created on May 22, 2013. The original closing date and the current closing date are both listed as September 7, 2016, and the archive date is October 8, 2016, indicating that this particular announcement is no longer open for new applications under that specific solicitation. The announcement also provides an NIH grants guide link for full details and points applicants to the NIH Office of Extramural Research webmaster contacts for technical difficulties accessing the posting.

Overall, PAR 13-231 can be understood as an NIH effort to ensure that embryonic and perinatal lethal knockout mouse lines are not simply cataloged as non-viable outcomes, but instead are examined in ways that reveal the developmental and mechanistic reasons for lethality and the potentially meaningful phenotypes present in heterozygotes. By encouraging targeted phenotyping while these lines are already being created and maintained within IMPC workflows, the FOA aims to maximize the scientific return on the large-scale public investment in knockout mouse production and to generate data that can translate into a deeper understanding of essential genes, developmental biology, and disease-relevant pathways.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Food and Nutrition Health Income Security and Social Services

Next opportunity: BLM OR WA Restoration and Conservation Projects, Eugene District Oregon

Previous opportunity: Transformation Initiative Rental Assistance Demonstration Small Research Grant Program

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 13 231

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 13 231) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 231", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.